Biopharmaceutical Contract Manufacturing Market Forecast by Monoclonal Antibodies, Vaccines, and Others from 2024 to 2034
Increased Outsourcing by Pharmaceutical Companies Seeking Cost-Efficiency, Expertise, and Flexibility in Manufacturing Processes
Biopharmaceutical Contract Manufacturing Market Overview for 2024 to 2034
The biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 8.8% during the projected period. The market value is expected to increase from USD 10.7 billion in 2024 to USD 25.1 billion by 2034.
Biopharmaceutical Contract Manufacturing Market Size, Analysis, and Insights
Biopharmaceutical companies are increasingly outsourcing their manufacturing processes to contract manufacturing organizations (CMOs) due to cost reduction initiatives and focus on core competencies.
The increasing demand for biopharmaceutical contract manufacturing is due to the complexity of biologic drugs that are difficult to manufacture and require specialized knowledge and expertise.
Many small and mid-sized biopharmaceutical companies lack the resources and expertise to manufacture biologics in-house, so they turn to contract manufacturing organizations (CMOs) to help them.
The market is expanding due to the rising demand for efficient and effective manufacturing processes are needed. These factors, along with technological advancements and the regulatory environment, have contributed to the increasing demand for biopharmaceutical contract manufacturing.
The trend driving the growth of biopharmaceutical contract manufacturing is the increasing use of cell and gene therapies. These therapies involve using living cells, which require specialized manufacturing processes.
Contract manufacturing organizations (CMOs) can provide the expertise and facilities needed to manufacture these complex therapies, which can be challenging for companies to do in-house.
Attributes
Details
Market Size, 2024
USD 10.7 billion
Market Size, 2034
USD 25.1 billion
Value CAGR (2024 to 2034)
8.8%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Key Opportunities in the Biopharmaceutical Contract Manufacturing Market
The demand for biopharmaceuticals, which are typically more complex and difficult to manufacture than traditional chemical drugs is increasing. As a result, many pharmaceutical companies are turning to contract manufacturers to help them produce these drugs at scale, which is expected to create lucrative opportunities in the market.
Pharmaceutical companies are looking to outsource their manufacturing operations to reduce costs, increase efficiency, and focus on their core competencies.
This trend is particularly strong in the biopharmaceutical sector, where a high degree of specialization and expertise is required to produce these complex drugs.
The increasing use of biologics in a wide range of therapeutic areas, the growing demand for personalized medicine, and the emergence of new manufacturing technologies that enable more efficient and cost-effective production of biopharmaceuticals are driving market growth.
Pharmaceutical companies can benefit from cost savings and efficiency gains that come with outsourcing, allowing them to focus on their core competencies and drive innovation in the biopharmaceutical sector.
Challenges for Biopharmaceutical Contract Manufacturers
The increasing complexity of biologics, the need for specialized facilities and equipment, and regulatory compliance act as restraints in the market.
Supply chain disruptions, high manufacturing costs, and the lack of skilled personnel restrict the market’s progress. Additionally, as demand for biologics continues to grow, manufacturers must balance the need for increased production, maintaining high-quality standards.
The risk of intellectual property theft is another challenge encountered by manufacturers. As contract manufacturers often work with multiple clients, there is a risk that confidential information could be shared or stolen. This can lead to legal disputes and damage to the reputation of the contract manufacturer.
The industry constantly evolves, with new technologies and processes emerging regularly. Contract manufacturers must stay current with the latest developments to remain competitive.
Find your sweet spots for generating winning opportunities in this market.
Category-wise Insights
The Mammalian-based Segment Dominates the Market by Platform Type
Attributes
Details
Top Platform Type
Mammalian-based
Market Share in 2024
73.0%
Mammalian cells are the most commonly used host cells for biologics production due to their ability to fold and modify complex proteins properly.
Mammalian-based manufacturing processes offer high yields, reproducibility, and scalability, which is crucial in meeting the high demand for biologics.
Regulatory agencies such as the FDA have strict guidelines for the manufacturing of biologics, and mammalian-based systems have a well-established track record of meeting these guidelines.
Advances in biotechnology and genetic engineering have led to the development of novel cell lines that can produce even more complex biologics, further solidifying the dominance of the mammalian-based segment in the biopharmaceutical contract manufacturing market.
The Monoclonal Antibodies Segment Dominates the Market by Product Type
Attributes
Details
Top Product Type
Monoclonal Antibodies
Market Share in 2024
51.0%
The monoclonal antibodies segment represents a significant share of 51.0% of the market in 2024.
The monoclonal antibodies segment dominates the biopharmaceutical contract manufacturing market due to its widespread use in treating various diseases such as cancer, autoimmune disorders, and infections.
Monoclonal antibodies are highly specific and can target specific cells and proteins, making them very effective in treating diseases.
The process of manufacturing monoclonal antibodies is well-established, making it easier for biopharmaceutical companies to outsource the production to contract manufacturing organizations. This has led to increased demand for contract manufacturing services in this segment.
The increasing prevalence of chronic diseases and the growing demand for personalized medicine are also expected to drive the growth of the monoclonal antibodies segment in the market.
Country-wise insights
Countries
CAGR through 2034
United States
9.0%
China
12.0%
India
11.0%
Japan
8.4%
Germany
10.5%
Biopharmaceutical Contract Manufacturing Market in the United States
The biopharmaceutical contract manufacturing market in the United States is expected to grow at a CAGR of 9.0% over the coming years. As pharmaceutical companies increasingly look to outsource manufacturing to specialized providers, the market is expanding.
Biopharmaceuticals are becoming more complex and specialized, requiring advanced manufacturing capabilities that many companies may not have in-house. Outsourcing to contract manufacturers allows these companies to leverage expertise and technology they may not have access to otherwise in the United States.
There is a growing trend toward outsourcing manufacturing to reduce costs and increase efficiency in the United States. Contract manufacturers can provide economies of scale that lead to lower costs for pharmaceutical companies.
Biopharmaceutical Contract Manufacturing Market in China
China's biopharmaceutical contract manufacturing market is experiencing a surge in demand due to several factors.
China has a large and aging population, leading to increased demand for healthcare products.
The Chinese government has been investing heavily in the biopharmaceutical industry, which has resulted in the sector's growth. Additionally, China's labor and production costs are relatively low compared to other countries, making it an attractive destination for biopharmaceutical companies looking to outsource their manufacturing processes.
China's regulatory environment has become more favorable to biopharmaceutical companies in recent years, which has helped to boost the industry's growth.
Biopharmaceutical Contract Manufacturing Market in India
India has a large pool of skilled and educated professionals, including scientists, engineers, and technicians, who are able to provide high-quality services to biopharmaceutical companies.
India's labor and production costs are relatively low compared to other countries, making it an attractive destination for outsourcing.
The Indian government has implemented several policies and initiatives to promote the growth of the biopharmaceutical sector, including tax incentives, streamlined regulatory processes, and investments in infrastructure and research and development.
India has a large market for biopharmaceutical products, driven by increasing healthcare awareness, rising disposable incomes, and a growing aging population.
Biopharmaceutical Contract Manufacturing Market in Japan
The country has a rapidly aging population that requires more advanced and innovative healthcare solutions.
There has been a significant increase in government funding for the biopharmaceutical industry, which has helped to spur growth in the market. Additionally, Japan is home to several major pharmaceutical companies, which have been investing heavily in research and development of new drugs.
All these factors have combined to create a highly favorable environment for biopharmaceutical contract manufacturing in Japan.
Japan's advanced technological capabilities, highly skilled workforce, and strict regulatory environment have made it an attractive destination for companies looking to outsource their biopharmaceutical manufacturing needs.
Biopharmaceutical Contract Manufacturing Market in Germany
Germany has a highly skilled workforce and a strong infrastructure in the biopharmaceutical sector. This means that there are plenty of talented professionals and facilities available to support the development and manufacture of biopharmaceuticals.
Germany has a well-established regulatory framework that ensures high standards of quality and safety in the biopharmaceutical industry. This gives companies and investors’ confidence in the reliability and consistency of the manufacturing process, which is crucial for the success of any biopharmaceutical product.
Germany has a large and growing market for biopharmaceuticals, both domestically and internationally. As the demand for these products continues to rise, there is a need for efficient and cost-effective manufacturing solutions, driving the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Competitive Landscape
The biopharmaceutical contract manufacturing market is becoming increasingly competitive due to the growing demand for biologics and biosimilars.
Companies have a strong reputation for providing high-quality contract manufacturing services to the biopharmaceutical industry. However, there are also several smaller players in the market that are gaining traction and competing with these larger companies by offering specialized services and innovative technologies.
Recent Developments
In 2021, Lonza Group Ag announced its largest sale of Lonza Speciality Ingredients to Bain Capital Private Equity for USD 4.4 billion.
In 2021, bzena Limited, a partner research organization for the integrated discovery of cGMP and a manufacturer of biopharmaceuticals solutions, worked with BiVictriX Therapeutics plc, a biotechnology business, to manufacture BiVictriX's antibody-drug conjugates (ADC).
In 2021, Novasep Company formed an exclusive cooperation with PharmaZell. The cooperation aims to develop, manufacture, and expand complicated small compounds and ADCs on a worldwide scale.